Pfizer files crizotinib applications for NSCLC in US, Japan
This article was originally published in Scrip
Executive Summary
The US FDA accepted for review Pfizer's new drug application (NDA) for crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, and granted the NDA a six-month priority review.